Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? | Hematol Oncol;42(2): e3259, 2024 Mar. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?

Duminuco, Andrea; Nardo, Antonella; Palumbo, Giuseppe A.

Affiliation

Duminuco A; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Nardo A; Division of Hematology and BMT Unit, A.O.U. Policlinico "G.Rodolico-San Marco", Catania, Italy.
Palumbo GA; Division of Hematology and BMT Unit, A.O.U. Policlinico "G.Rodolico-San Marco", Catania, Italy.

Hematol Oncol ; 42(2): e3259, 2024 Mar.

Article in En | MEDLINE | ID: mdl-38402568

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Lymphoproliferative Disorders / Nitriles Limits: Humans Language: En Journal: Hematol Oncol Year: 2024 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Lymphoproliferative Disorders / Nitriles Limits: Humans Language: En Journal: Hematol Oncol Year: 2024 Document type: Article Country of publication: